Lenalidomide (Revlimid®, CC-5013) in Subjects With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma

New York Medical Center, MBCCOP, The Bronx

Signal Point Hematology/Oncology, Middletown

Gunderson Clinic, Ltd., La Crosse

Mayo Clinic, Rochester

Rush University Medical Center, Chicago

Mayo Clinic Scottsdale, Scottsdale

Pacific Coast Hematology/Oncology Medical Group, Onc., Fountain Valley

Alta Bates Cancer Center, Berkeley

Swedish Cancer Institute, Seattle

Harvard University, Boston

University of Nebraska, Omaha

BC Community Oncology Trialist, Burnaby

BC Community Oncology, North Vancouver

London Regional Cancer Program, London

University of Saskatchewan, Saskatoon